MGX
Metagenomi, Inc. Common Stock
NASDAQ: MGX · HEALTHCARE · BIOTECHNOLOGY
$1.38
+2.22% today
Updated 2026-04-30
Market cap
$55.68M
P/E ratio
—
P/S ratio
2.21x
EPS (TTM)
$-2.36
Dividend yield
—
52W range
$1 – $4
Volume
0.2M
Metagenomi, Inc. Common Stock (MGX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $243000.00 | $17.20M | $44.76M | $52.30M | $25.21M |
| Revenue growth (YoY) | — | +6978.2% | +160.2% | +16.8% | -51.8% |
| Cost of revenue | $387000.00 | $1.73M | $94.40M | $5.41M | $5.32M |
| Gross profit | $-144000.00 | $15.47M | $-49.65M | $52.30M | $19.89M |
| Gross margin | -59.3% | 89.9% | -110.9% | 100.0% | 78.9% |
| R&D | $14.48M | $43.14M | $94.40M | $109.18M | $94.43M |
| SG&A | $9.71M | $18.70M | $28.84M | $32.02M | $26.79M |
| Operating income | $-23.95M | $-44.64M | $-78.49M | $-88.90M | $-96.01M |
| Operating margin | -9854.7% | -259.5% | -175.4% | -170.0% | -380.9% |
| EBITDA | $-20.75M | $-39.19M | $-74.28M | $-83.49M | $-90.70M |
| EBITDA margin | -8540.3% | -227.9% | -166.0% | -159.7% | -359.8% |
| EBIT | $-21.14M | $-40.93M | $-78.49M | $-88.90M | $-96.01M |
| Interest expense | $302000.00 | $98000.00 | $0.00 | — | — |
| Income tax | $306000.00 | $2.57M | $8.03M | $-5.51M | — |
| Effective tax rate | -1.4% | -6.3% | -13.3% | 6.6% | 0.0% |
| Net income | $-21.44M | $-43.59M | $-68.25M | $-78.06M | $-87.87M |
| Net income growth (YoY) | — | -103.3% | -56.6% | -14.4% | -12.6% |
| Profit margin | -8823.9% | -253.4% | -152.5% | -149.3% | -348.5% |